ifosfamide has been researched along with Encephalopathy, Toxic in 50 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Following the 20th week of ifosfamide treatment, the patient's follow-up with the diagnosis of osteosarcoma developed neurological findings." | 8.02 | Ifosfamide induced encephalopathy in a child with osteosarcoma. ( Atay, AA; Demir, ÜF; Malbora, B; Sarbay, H; Yılmaz, G, 2021) |
| "Ifosfamide combined with other antineoplastic agents has been effective in the treatment of osteosarcoma, although adverse effects are reported in the increasing use of ifosfamide." | 7.80 | Effects of blood purification therapy on a patient with ifosfamide-induced neurotoxicity and acute kidney injury. ( Enokida, H; Hayami, H; Komiya, S; Nagano, S; Nakagawa, M; Nishimura, H; Yokouchi, M, 2014) |
| "We retrospectively examined the incidence, severity, and risk factors of ifosfamide encephalopathy in 61 Japanese patients with bone and soft tissue sarcomas at our institution." | 7.76 | Ifosfamide encephalopathy associated with chemotherapy for musculoskeletal sarcomas: incidence, severity, and risk factors. ( Kikuchi, S; Konno, S; Tajino, T; Takeda, A; Yamada, H, 2010) |
| "To report two cases of recurrent uterine sarcoma that developed ifosfamide-induced encephalopathy (IIE) with successful management." | 7.76 | Ifosfamide-induced encephalopathy in patients with uterine sarcoma. ( Chang, FW; Liu, YL; Tsai, SH; Yu, MH, 2010) |
| "Ifosfamide has been shown to be associated with encephalopathy in 10-40% of patients." | 5.43 | Severe post-treatment leukopenia associated with the development of encephalopathy following ifosfamide infusion. ( Isola, LM; Kim, SS; Oh, WK, 2016) |
| "Generalized myoclonus was most common, occurring in four patients while postural tremor was documented in the other three." | 5.37 | Ifosfamide associated myoclonus-encephalopathy syndrome. ( Josephs, KA; Rabinstein, AA; Savica, R, 2011) |
| "Ifosfamide is relatively well tolerated but it can be associated occasionally with life-threatening complications such as arrhythmias and heart failure, severe encephalopathy and hemorrhagic cystitis." | 4.82 | Side effects of ifosfamide. ( Klastersky, J, 2003) |
| "Following the 20th week of ifosfamide treatment, the patient's follow-up with the diagnosis of osteosarcoma developed neurological findings." | 4.02 | Ifosfamide induced encephalopathy in a child with osteosarcoma. ( Atay, AA; Demir, ÜF; Malbora, B; Sarbay, H; Yılmaz, G, 2021) |
| "To determine whether thiamine prophylaxis decreases the incidence of ifosfamide-induced encephalopathy in patients receiving ifosfamide for the treatment of lymphoma." | 3.96 | Evaluation of thiamine for the prevention of ifosfamide-induced encephalopathy. ( Ayarza, M; Clark, SM; Hairston, A; Lentz, KL; Liu, B; Morgan, KP; Wind, LS, 2020) |
| "A retrospective study of sarcoma and lymphoma patients receiving ifosfamide chemotherapy was performed at the participating institutions." | 3.81 | An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center. ( Butrynski, J; Cirrone, F; Feng, Y; Fisher, DC; Harris, C; McDonnell, AM; Neuberg, D; Szabatura, AH; Voit, D, 2015) |
| "Ifosfamide combined with other antineoplastic agents has been effective in the treatment of osteosarcoma, although adverse effects are reported in the increasing use of ifosfamide." | 3.80 | Effects of blood purification therapy on a patient with ifosfamide-induced neurotoxicity and acute kidney injury. ( Enokida, H; Hayami, H; Komiya, S; Nagano, S; Nakagawa, M; Nishimura, H; Yokouchi, M, 2014) |
| "We retrospectively examined the incidence, severity, and risk factors of ifosfamide encephalopathy in 61 Japanese patients with bone and soft tissue sarcomas at our institution." | 3.76 | Ifosfamide encephalopathy associated with chemotherapy for musculoskeletal sarcomas: incidence, severity, and risk factors. ( Kikuchi, S; Konno, S; Tajino, T; Takeda, A; Yamada, H, 2010) |
| "To report two cases of recurrent uterine sarcoma that developed ifosfamide-induced encephalopathy (IIE) with successful management." | 3.76 | Ifosfamide-induced encephalopathy in patients with uterine sarcoma. ( Chang, FW; Liu, YL; Tsai, SH; Yu, MH, 2010) |
| "A retrospective study of inpatients with sarcoma who received a two or four-day regimen of MAI (mesna, doxorubicin, and ifosfamide) between January 1, 2004 and December 31, 2006 was conducted." | 3.74 | Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant. ( Hatfield Seung, A; Howell, JE; Nesbit, SA; Szabatura, AH, 2008) |
| "Ifosfamide is an alkylating agent used in the treatment of germ-cell tumors, sarcomas and lymphomas." | 3.73 | [Ifosfamide induced encephalopathy: 15 observations]. ( Behar, C; Dufour, C; Grill, J; Hartmann, O; Motte, J; Munzer, M; Oberlin, O; Paci, A; Sabouraud, P, 2006) |
| " During the initial therapy, an ifosfamide-induced encephalopathy occurred as status epilepticus." | 3.72 | Prophylactic treatment of known ifosfamide-induced encephalopathy for chemotherapy with high-dose ifosfamide? ( Bellos, F; Egerer, G; Harter, C; Ho, AD; Kasper, B; Krasniqi, F; Meissner, J, 2004) |
| " Aprepitant is administered as an anti-emetic agent in chemotherapy and regarding the inhibitory effect on CYP3A4, aprepitant can increase the risk of ifosfamide adverse effects." | 2.82 | Aprepitant, fosaprepitant and risk of ifosfamide-induced neurotoxicity: a systematic review. ( Mohammadpour, AH; Rahimi, H; Sadeghi, M; Samadi, S; Vazirian, F, 2022) |
| "Prolonged encephalopathy and MB therapy has not been described in the literature as lasting longer than 30 days following treatment." | 2.82 | A novel case of prolonged Ifosfamide encephalopathy and long-term treatment with methylene blue: a case report and review of literature. ( Campino, GA; Chain, G; Kalia, M; Kestenbaum, K; Pappas, L; Sechser-Perl, A; Zaghloul, N, 2022) |
| "Ifosfamide is a chemotherapy agent commonly used in the treatment of several solid tumors and hematologic malignancies." | 2.44 | Ifosfamide neuropsychiatric toxicity in patients with cancer. ( Alici-Evcimen, Y; Breitbart, WS, 2007) |
| "Ifosfamide is an alkylating agent with well-demonstrated efficacy against a large number of malignant diseases." | 2.42 | Neurological toxicity of ifosfamide. ( Giometto, B; Nicolao, P, 2003) |
| " In most clinical pharmacokinetic studies, the phenomenon of autoinduction has been observed, but the mechanism is not completely understood." | 2.41 | Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. ( Beijnen, JH; de Kraker, J; Groen, HJ; Jansen, RL; Keizer, HJ; Kerbusch, T; Schellens, JH; van Putten, JW, 2001) |
| "Ifosfamide-related encephalopathy commonly results in a distinct pattern of generalized periodic discharges admixed with intermittent background attenuation on EEG." | 1.51 | Clinical and EEG Characteristics of Ifosfamide-Related Encephalopathy. ( Chen, X; Gusdon, AM; Malani, R, 2019) |
| "Ifosfamide has been shown to be associated with encephalopathy in 10-40% of patients." | 1.43 | Severe post-treatment leukopenia associated with the development of encephalopathy following ifosfamide infusion. ( Isola, LM; Kim, SS; Oh, WK, 2016) |
| "Ifosfamide (IFOS) which is a cytotoxic alkylating agent may cause central nervous system toxicity." | 1.40 | Effect of alpha lipoic acid on ifosfamide-induced central neurotoxicity in rats. ( Albayrak, A; Bilen, S; Fadillioglu, E; Ginis, Z; Kurt, SN; Ozturk, G, 2014) |
| "A serious adverse effect that can limit the utility of ifosfamide is neurotoxicity, known as ifosfamide-induced encephalopathy (IIE)." | 1.37 | Evaluation of methylene blue, thiamine, and/or albumin in the prevention of ifosfamide-related neurotoxicity. ( Marshall, H; McQuary, A; Richards, A, 2011) |
| "Generalized myoclonus was most common, occurring in four patients while postural tremor was documented in the other three." | 1.37 | Ifosfamide associated myoclonus-encephalopathy syndrome. ( Josephs, KA; Rabinstein, AA; Savica, R, 2011) |
| "Ifosfamide is an alkylating agent used in the treatment of several neoplasias." | 1.36 | Severe ifosfamide-induced neurotoxicity: a case report. ( Breña Atienza, J; Cabello Rodríguez, A; Cháfer Rudilla, M; Merino Alonso, J; Ramos Linares, S; Ríos Rull, P, 2010) |
| "One of our patient's encephalopathy and abnormal movements may have improved after the administration of methylene blue and thiamine." | 1.36 | Ifosfamide-induced encephalopathy and movement disorder. ( Ames, B; Chaffee, S; Kim, J; Lewis, LD; Morse, R, 2010) |
| " In the previous five cycles of ifosfamide, carboplatin, and etoposide, the patient had no problems with the neurotoxic adverse effects associated with ifosfamide use." | 1.35 | Possible contribution of aprepitant to ifosfamide-induced neurotoxicity. ( Jarkowski, A, 2008) |
| "Ifosfamide is a well known prodrug for cancer treatment with cytochrome P450 metabolism." | 1.35 | New ifosfamide analogs designed for lower associated neurotoxicity and nephrotoxicity with modified alkylating kinetics leading to enhanced in vitro anticancer activity. ( Bourget, P; Deroussent, A; Martens, T; Mercier, L; Munier, F; Paci, A; Prost, E; Re, M; Royer, J; Storme, T; Vassal, G, 2009) |
| " The authors' multidimensional analysis model revealed that besides the total ifosfamide dose and co-administration of other toxic drugs, polymorphic locus of GSTP1 gene may be one of the factors determining a higher toxicity of the cytostatic agent." | 1.33 | Role of GSTM1, GSTP1, and GSTT1 gene polymorphism in ifosfamide metabolism affecting neurotoxicity and nephrotoxicity in children. ( Misiura, K; Zielińska, E; Zubowska, M, 2005) |
| "Thiamine appears to be a safe and effective treatment for reversing encephalopathy resulting form ifosfamide infusion, without any significant side effects." | 1.33 | Role of thiamine in managing ifosfamide-induced encephalopathy. ( Awan, F; Hamadani, M, 2006) |
| "08) and dosage (median 2." | 1.32 | Incidence and severity of ifosfamide-induced encephalopathy. ( Fiegl, M; Ostermann, H; Rieger, C; Schiel, X; Tischer, J, 2004) |
| "Ifosfamide is an antineoplastic agent that requires hepatic activation to the cytotoxic active metabolite ifosforamide mustard." | 1.30 | Suspected ifosfamide-induced neurotoxicity. ( McVay, JI; Wood, AM, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.00) | 18.2507 |
| 2000's | 23 (46.00) | 29.6817 |
| 2010's | 20 (40.00) | 24.3611 |
| 2020's | 6 (12.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chain, G | 1 |
| Kalia, M | 1 |
| Kestenbaum, K | 1 |
| Pappas, L | 1 |
| Sechser-Perl, A | 1 |
| Campino, GA | 1 |
| Zaghloul, N | 1 |
| Vazirian, F | 1 |
| Samadi, S | 1 |
| Rahimi, H | 1 |
| Sadeghi, M | 1 |
| Mohammadpour, AH | 1 |
| Sowell, H | 1 |
| Gatwood, K | 1 |
| Perciavalle, M | 1 |
| Kiani, A | 1 |
| Nik, SH | 1 |
| Khodadoost, A | 1 |
| Salimi, A | 1 |
| Pourahmad, J | 1 |
| Sarbay, H | 1 |
| Demir, ÜF | 1 |
| Yılmaz, G | 1 |
| Atay, AA | 1 |
| Malbora, B | 1 |
| Gusdon, AM | 1 |
| Malani, R | 1 |
| Chen, X | 1 |
| Lentz, KL | 1 |
| Clark, SM | 1 |
| Ayarza, M | 1 |
| Liu, B | 1 |
| Morgan, KP | 1 |
| Wind, LS | 1 |
| Hairston, A | 1 |
| Ozturk, G | 2 |
| Ginis, Z | 2 |
| Kurt, SN | 2 |
| Albayrak, A | 2 |
| Bilen, S | 1 |
| Fadillioglu, E | 2 |
| Nishimura, H | 1 |
| Enokida, H | 1 |
| Nagano, S | 1 |
| Yokouchi, M | 1 |
| Hayami, H | 1 |
| Komiya, S | 1 |
| Nakagawa, M | 1 |
| Albayrak, M | 1 |
| Szabatura, AH | 2 |
| Cirrone, F | 1 |
| Harris, C | 1 |
| McDonnell, AM | 1 |
| Feng, Y | 1 |
| Voit, D | 1 |
| Neuberg, D | 1 |
| Butrynski, J | 1 |
| Fisher, DC | 1 |
| Peddi, PF | 1 |
| Peddi, S | 1 |
| Santos, ES | 1 |
| Morgensztern, D | 1 |
| Kim, SS | 1 |
| Isola, LM | 1 |
| Oh, WK | 1 |
| Sunela, K | 1 |
| Bärlund, M | 1 |
| Howell, JE | 1 |
| Hatfield Seung, A | 1 |
| Nesbit, SA | 1 |
| Storme, T | 1 |
| Deroussent, A | 1 |
| Mercier, L | 1 |
| Prost, E | 1 |
| Re, M | 1 |
| Munier, F | 1 |
| Martens, T | 1 |
| Bourget, P | 1 |
| Vassal, G | 1 |
| Royer, J | 1 |
| Paci, A | 2 |
| Jarkowski, A | 1 |
| Di Cataldo, A | 1 |
| Astuto, M | 1 |
| Rizzo, G | 1 |
| Bertuna, G | 1 |
| Russo, G | 1 |
| Incorpora, G | 1 |
| Lombardi, G | 1 |
| Zustovich, F | 1 |
| Nicoletto, MO | 1 |
| Donach, M | 1 |
| Pastorelli, D | 1 |
| Yuen, C | 1 |
| Ames, B | 1 |
| Lewis, LD | 1 |
| Chaffee, S | 1 |
| Kim, J | 1 |
| Morse, R | 1 |
| Ramos Linares, S | 1 |
| Breña Atienza, J | 1 |
| Cháfer Rudilla, M | 1 |
| Ríos Rull, P | 1 |
| Cabello Rodríguez, A | 1 |
| Merino Alonso, J | 1 |
| Bernard, PA | 1 |
| McCabe, T | 1 |
| Bayliff, S | 1 |
| Hayes, D | 1 |
| Tajino, T | 1 |
| Kikuchi, S | 1 |
| Yamada, H | 1 |
| Takeda, A | 1 |
| Konno, S | 1 |
| Janeway, KA | 1 |
| Grier, HE | 1 |
| Liu, YL | 1 |
| Tsai, SH | 1 |
| Chang, FW | 1 |
| Yu, MH | 1 |
| Kettle, JK | 1 |
| Grauer, D | 1 |
| Folker, TL | 1 |
| O'Neal, N | 1 |
| Henry, DW | 1 |
| Williams, CB | 1 |
| Richards, A | 1 |
| Marshall, H | 1 |
| McQuary, A | 1 |
| Imtiaz, S | 1 |
| Muzaffar, N | 1 |
| Savica, R | 1 |
| Rabinstein, AA | 1 |
| Josephs, KA | 1 |
| Turner, AR | 1 |
| Duong, CD | 1 |
| Good, DJ | 1 |
| Klastersky, J | 1 |
| Nicolao, P | 1 |
| Giometto, B | 1 |
| Kasper, B | 1 |
| Harter, C | 1 |
| Meissner, J | 1 |
| Bellos, F | 1 |
| Krasniqi, F | 1 |
| Ho, AD | 1 |
| Egerer, G | 1 |
| Raj, AB | 1 |
| Bertolone, SJ | 1 |
| Jaffe, N | 1 |
| Rieger, C | 1 |
| Fiegl, M | 1 |
| Tischer, J | 1 |
| Ostermann, H | 1 |
| Schiel, X | 1 |
| Kerdudo, C | 1 |
| Orbach, D | 1 |
| Sarradet, JL | 1 |
| Doz, F | 1 |
| Zielińska, E | 1 |
| Zubowska, M | 1 |
| Misiura, K | 1 |
| Dufour, C | 1 |
| Grill, J | 1 |
| Sabouraud, P | 1 |
| Behar, C | 1 |
| Munzer, M | 1 |
| Motte, J | 1 |
| Oberlin, O | 1 |
| Hartmann, O | 1 |
| Patel, PN | 1 |
| Hamadani, M | 1 |
| Awan, F | 1 |
| Alici-Evcimen, Y | 1 |
| Breitbart, WS | 1 |
| Ajithkumar, T | 1 |
| Parkinson, C | 1 |
| Shamshad, F | 1 |
| Murray, P | 1 |
| Brunello, A | 1 |
| Basso, U | 1 |
| Rossi, E | 1 |
| Stefani, M | 1 |
| Ghiotto, C | 1 |
| Marino, D | 1 |
| Crivellari, G | 1 |
| Monfardini, S | 1 |
| McVay, JI | 1 |
| Wood, AM | 1 |
| Kerbusch, T | 1 |
| de Kraker, J | 1 |
| Keizer, HJ | 1 |
| van Putten, JW | 1 |
| Groen, HJ | 1 |
| Jansen, RL | 1 |
| Schellens, JH | 1 |
| Beijnen, JH | 1 |
| Stewart, SL | 1 |
| Nielsen, E | 1 |
| Brant, J | 1 |
| Primavera, A | 1 |
| Audenino, D | 1 |
| Cocito, L | 1 |
| Meyer, T | 1 |
| Ludolph, AC | 1 |
| Münch, C | 1 |
12 reviews available for ifosfamide and Encephalopathy, Toxic
| Article | Year |
|---|---|
A novel case of prolonged Ifosfamide encephalopathy and long-term treatment with methylene blue: a case report and review of literature.
Topics: Brain Diseases; Child; Female; Humans; Ifosfamide; Methylene Blue; Neurotoxicity Syndromes; Sleepine | 2022 |
Aprepitant, fosaprepitant and risk of ifosfamide-induced neurotoxicity: a systematic review.
Topics: Aprepitant; Humans; Ifosfamide; Morpholines; Neurotoxicity Syndromes; Randomized Controlled Trials a | 2022 |
Central nervous system toxicities of chemotherapeutic agents.
Topics: Antineoplastic Agents; Central Nervous System Diseases; Cisplatin; Cytarabine; Fluorouracil; Humans; | 2014 |
[Treatment and prevention of iphosphamide-induced encephalopathy].
Topics: Antiemetics; Antineoplastic Agents, Alkylating; Aprepitant; Drug Interactions; Enzyme Inhibitors; Hu | 2016 |
Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects.
Topics: Antidotes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Doxorubicin; H | 2010 |
Side effects of ifosfamide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Cystitis; Drug Interactions; Heart; Hemorrhage; H | 2003 |
Neurological toxicity of ifosfamide.
Topics: Acetaldehyde; Animals; Antineoplastic Agents, Alkylating; Brain; Carbocysteine; Central Nervous Syst | 2003 |
Methylene blue for management of Ifosfamide-induced encephalopathy.
Topics: Humans; Ifosfamide; MEDLINE; Methylene Blue; Neurotoxicity Syndromes; Time Factors; Treatment Outcom | 2006 |
Ifosfamide neuropsychiatric toxicity in patients with cancer.
Topics: Adult; Antineoplastic Agents, Alkylating; Burkitt Lymphoma; Delusions; Enzyme Inhibitors; Female; Hu | 2007 |
Ifosfamide encephalopathy.
Topics: Antineoplastic Agents, Alkylating; Humans; Ifosfamide; Neurotoxicity Syndromes | 2007 |
Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.
Topics: Animals; Antineoplastic Agents, Alkylating; Area Under Curve; Cyclophosphamide; Cytochrome P-450 Enz | 2001 |
Chemotherapy-induced neurotoxicity: assessment and interventions for patients at risk.
Topics: Antineoplastic Agents; Cisplatin; Cytarabine; Humans; Ifosfamide; Methotrexate; Neoplasms; Neurotoxi | 2002 |
38 other studies available for ifosfamide and Encephalopathy, Toxic
| Article | Year |
|---|---|
Incidence and severity of ICANS following CAR-T therapy in patients previously receiving ifosfamide.
Topics: Humans; Ifosfamide; Immunotherapy, Adoptive; Incidence; Neurotoxicity Syndromes; Patients; Receptors | 2023 |
Trifluoperazine an Antipsychotic Drug and Inhibitor of Mitochondrial Permeability Transition Protects Cytarabine and Ifosfamide-Induced Neurotoxicity.
Topics: Animals; Antineoplastic Agents; Brain; Cells, Cultured; Cytarabine; Disease Models, Animal; Humans; | 2020 |
Ifosfamide induced encephalopathy in a child with osteosarcoma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Neoplasms; Brain Diseases; Female; Humans; Ifosf | 2021 |
Clinical and EEG Characteristics of Ifosfamide-Related Encephalopathy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Diseases; Electroencephalography; | 2019 |
Evaluation of thiamine for the prevention of ifosfamide-induced encephalopathy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Carboplatin; Cohort Studies; Etoposi | 2020 |
Effect of alpha lipoic acid on ifosfamide-induced central neurotoxicity in rats.
Topics: Animals; Antioxidants; Brain; Caspase 3; Catalase; Ifosfamide; Male; Malondialdehyde; Neurons; Neuro | 2014 |
Effects of blood purification therapy on a patient with ifosfamide-induced neurotoxicity and acute kidney injury.
Topics: Acute Kidney Injury; Adolescent; Antineoplastic Agents, Alkylating; Bone Neoplasms; Female; Hemodiaf | 2014 |
Protective effects of caffeic acid phenethyl ester on ifosfamide-induced central neurotoxicity in rats.
Topics: Animals; Antioxidants; Brain; Caffeic Acids; Catalase; Ifosfamide; Immunohistochemistry; Lipid Perox | 2016 |
An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center.
Topics: Antineoplastic Agents, Alkylating; Brain Diseases; Cancer Care Facilities; Cisplatin; Female; Humans | 2015 |
Severe post-treatment leukopenia associated with the development of encephalopathy following ifosfamide infusion.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Female; Humans; Ifosf | 2016 |
Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant.
Topics: Antidotes; Antiemetics; Antineoplastic Agents, Alkylating; Aprepitant; Delirium; Female; Humans; Ifo | 2008 |
New ifosfamide analogs designed for lower associated neurotoxicity and nephrotoxicity with modified alkylating kinetics leading to enhanced in vitro anticancer activity.
Topics: Animals; Antineoplastic Agents, Alkylating; Biotransformation; Cells, Cultured; Humans; Ifosfamide; | 2009 |
Possible contribution of aprepitant to ifosfamide-induced neurotoxicity.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carboplatin; Dexamet | 2008 |
Neurotoxicity during ifosfamide treatment in children.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Cyclophosphamide; Female; Hu | 2009 |
Important role of thiamine in preventing ifosfamide-induced encephalopathy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Female; Humans; Ifosfamide; Middl | 2010 |
Aprepitant-associated ifosfamide neurotoxicity.
Topics: Adult; Antidepressive Agents; Antineoplastic Agents, Alkylating; Aprepitant; Case-Control Studies; F | 2010 |
Ifosfamide-induced encephalopathy and movement disorder.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Neoplasms; Brain Diseases; Child; Female; Humans | 2010 |
Severe ifosfamide-induced neurotoxicity: a case report.
Topics: Adult; Antineoplastic Agents, Alkylating; Hodgkin Disease; Humans; Ifosfamide; Male; Neurotoxicity S | 2010 |
Successful treatment of ifosfamide neurotoxicity with dexmedetomidine.
Topics: Adrenergic alpha-2 Receptor Agonists; Antidotes; Antineoplastic Agents, Alkylating; Child, Preschool | 2010 |
Ifosfamide encephalopathy associated with chemotherapy for musculoskeletal sarcomas: incidence, severity, and risk factors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Cisplatin; Dose-R | 2010 |
Ifosfamide-induced encephalopathy in patients with uterine sarcoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Female; Humans; Ifosfamide; Methylene Blue; Middle Aged; Ne | 2010 |
Effectiveness of exogenous albumin administration for the prevention of ifosfamide-induced encephalopathy.
Topics: Academic Medical Centers; Adult; Aged; Female; Humans; Hypoalbuminemia; Ifosfamide; Male; Middle Age | 2010 |
Evaluation of methylene blue, thiamine, and/or albumin in the prevention of ifosfamide-related neurotoxicity.
Topics: Adult; Drug Evaluation; Drug Therapy, Combination; Humans; Ifosfamide; Methylene Blue; Middle Aged; | 2011 |
Ifosfamide neurotoxicty in a young female with a remarkable response to thiamine.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Central Ne | 2010 |
Ifosfamide associated myoclonus-encephalopathy syndrome.
Topics: Antineoplastic Agents, Alkylating; Databases, Factual; Dyskinesia, Drug-Induced; Female; Humans; Ifo | 2011 |
Methylene blue for the treatment and prophylaxis of ifosfamide-induced encephalopathy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Female; Humans; Ifosfamide; Male; Methylene Blue; Ne | 2003 |
Prophylactic treatment of known ifosfamide-induced encephalopathy for chemotherapy with high-dose ifosfamide?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemoprevention; Female; Huma | 2004 |
Methylene blue reversal of ifosfamide-related encephalopathy.
Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Electroencephalography; Enzyme Inhibitors; | 2004 |
Incidence and severity of ifosfamide-induced encephalopathy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Cohort Studies; Dose-Response Relationship, Drug; Fe | 2004 |
Ifosfamide neurotoxicity: an atypical presentation with psychiatric manifestations.
Topics: Acute Disease; Adolescent; Antineoplastic Agents, Alkylating; Bipolar Disorder; Humans; Ifosfamide; | 2006 |
Role of GSTM1, GSTP1, and GSTT1 gene polymorphism in ifosfamide metabolism affecting neurotoxicity and nephrotoxicity in children.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Cyclophosph | 2005 |
[Ifosfamide induced encephalopathy: 15 observations].
Topics: Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Coma; Enzyme Inhibitors; Fat | 2006 |
Role of thiamine in managing ifosfamide-induced encephalopathy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Female; Humans; Ifosfamide; Male; Middle Aged; Neuro | 2006 |
Ifosfamide-related encephalopathy in elderly patients : report of five cases and review of the literature.
Topics: Abdominal Neoplasms; Aged; Antidotes; Antineoplastic Agents, Alkylating; Antineoplastic Combined Che | 2007 |
Suspected ifosfamide-induced neurotoxicity.
Topics: Adult; Antineoplastic Agents, Alkylating; Humans; Ifosfamide; Male; Neurotoxicity Syndromes | 1999 |
Postchemotherapy confusion.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Female; Humans; Ifosfamide; M | 2001 |
Ifosfamide encephalopathy and nonconvulsive status epilepticus.
Topics: Adult; Anticonvulsants; Antineoplastic Agents, Alkylating; Diazepam; Electroencephalography; Epileps | 2002 |
Ifosfamide encephalopathy presenting with asterixis.
Topics: Dyskinesia, Drug-Induced; Dyskinesias; Electroencephalography; Humans; Ifosfamide; Magnetic Resonanc | 2002 |